ZA965368B - A pharmaceutical formulation - Google Patents

A pharmaceutical formulation

Info

Publication number
ZA965368B
ZA965368B ZA965368A ZA965368A ZA965368B ZA 965368 B ZA965368 B ZA 965368B ZA 965368 A ZA965368 A ZA 965368A ZA 965368 A ZA965368 A ZA 965368A ZA 965368 B ZA965368 B ZA 965368B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
ZA965368A
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmega Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA965368B publication Critical patent/ZA965368B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA965368A 1995-07-14 1996-06-25 A pharmaceutical formulation ZA965368B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14

Publications (1)

Publication Number Publication Date
ZA965368B true ZA965368B (en) 1997-01-14

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965368A ZA965368B (en) 1995-07-14 1996-06-25 A pharmaceutical formulation

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155L (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2290081A3 (en) 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
ES2323220T3 (en) 2000-01-13 2009-07-09 Genentech, Inc. STRA6 HUMAN POLYPEPTIDES.
KR20080011353A (en) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 Non-aqueous injections for the sustained release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
JP2003528149A (en) 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド Use of insulin for the treatment of cartilage disorders
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA03000073A (en) 2000-06-26 2003-09-25 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (en) 2000-08-07 2004-05-27 ネクター セラピューティックス Inhalable, spray-dried, 4-helix bundle protein powder with minimal aggregates
DE60136281D1 (en) 2000-08-24 2008-12-04 Genentech Inc METHOD FOR INHIBITING IL-22-INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
JP2005518212A (en) 2002-02-25 2005-06-23 ジェネンテック・インコーポレーテッド Novel type 1 cytokine receptor GLM-R
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
MXPA06000347A (en) 2003-07-08 2006-03-28 Genentech Inc Il-17 a/f heterologous polypeptides and therapeutic uses thereof.
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
KR101204286B1 (en) 2004-03-30 2012-11-26 엔에스진 에이/에스 Therapeutic use of a growth factor, NsG33
CN101947310A (en) 2004-10-27 2011-01-19 丹佛大学 Thyroliberin analog and associated method
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
ES2391334T3 (en) 2005-06-21 2012-11-23 Xoma Technology Ltd. Antibodies and fragments thereof that bind to IL-1beta
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
JP2009504183A (en) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
ES2357626T3 (en) 2005-08-24 2011-04-28 The Rockefeller University PLANT-GBS MUTING LISINS.
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2633554C (en) 2005-12-22 2012-11-13 Genetech, Inc. Recombinant production of heparin binding proteins
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
SG170728A1 (en) 2006-03-23 2011-05-30 Novartis Ag Anti-tumor cell antigen antibody therapeutics
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
EP2010662A2 (en) 2006-04-19 2009-01-07 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CN101505789A (en) * 2006-07-06 2009-08-12 株式会社大熊 Stable liquid formulation of human growth hormone
AU2007333635B2 (en) 2006-12-20 2014-02-20 Xoma (Us) Llc Treatment of IL-1-beta related diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
MX2010006823A (en) 2007-12-20 2010-09-30 Xoma Technology Ltd Methods for the treatment of gout.
KR20170138580A (en) 2008-08-15 2017-12-15 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011047267A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED PORCINE GROWTH HORMONE POLYPEPTIDES AND USES THEREOF
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
BR112012017535A2 (en) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University use of vanadium compounds for bone healing
UA108636C2 (en) 2010-02-17 2015-05-25 PEPTIDE
EP2550018B1 (en) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
SI2585045T1 (en) 2010-06-24 2019-11-29 Hoffmann La Roche Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
LT2603232T (en) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. STABLE PHARMACEUTICAL FORM OF LINACLOTIDE
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
JP6149226B2 (en) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ Treatment of allodynia, hyperalgesia, spontaneous pain and phantom limb pain
EP2624852B1 (en) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Diagnostic and therapeutic uses of moesin fragments
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012167271A1 (en) * 2011-06-02 2012-12-06 Baxter International Inc. Formulations of recombinant furin
ES2614864T3 (en) 2011-08-17 2017-06-02 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
HRP20230153T1 (en) 2011-10-31 2023-03-31 F. Hoffmann-La Roche Ag Anti-il13 antibody formulations
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
EP2802603A4 (en) 2012-01-09 2015-11-04 Scripps Research Inst ULTRALANGE COMPLEMENTARITY RATINGS AND USES THEREOF
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN111518199A (en) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014318579A1 (en) 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
JP2021526837A (en) 2018-06-12 2021-10-11 アンジーエックス・インコーポレーテッド Antibody-oligonucleotide conjugate
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN119409834A (en) 2019-08-12 2025-02-11 北京恩瑞尼生物科技股份有限公司 Methods and compositions for promoting and enhancing T cell-mediated immune responses through ADCC targeting of CD39 expressing cells
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
US12583900B2 (en) 2019-12-04 2026-03-24 The Scripps Research Institute Peptide conjugates and methods of use
US12527875B2 (en) 2020-02-19 2026-01-20 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
JP2024517759A (en) 2021-04-28 2024-04-23 ミノトール セラピューティクス インコーポレイテッド Humanized chimeric bovine antibodies and methods of use
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
JP2024522196A (en) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート Long-acting dual gip/glp-1 peptide conjugates and methods of use - Patents.com
JP2024546758A (en) 2021-12-10 2024-12-26 ホバ セラピューティクス エーピーエス Treating nociceptive pain
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating eosinophil driven diseases and disorders
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1992017200A2 (en) * 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
NO980155D0 (en) 1998-01-13
CZ9498A3 (en) 1998-06-17
NO980155L (en) 1998-01-13
JPH11509212A (en) 1999-08-17
PL324379A1 (en) 1998-05-25
CA2226523A1 (en) 1997-02-06
MX9800358A (en) 1998-07-31
WO1997003692A1 (en) 1997-02-06
HUP9802287A2 (en) 1999-02-01
HUP9802287A3 (en) 2000-10-30
KR19990028981A (en) 1999-04-15
CN1190897A (en) 1998-08-19
BR9609741A (en) 1999-03-16
AU715997B2 (en) 2000-02-17
EP0839049A1 (en) 1998-05-06
AU6353496A (en) 1997-02-18
IL122583A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
ZA965368B (en) A pharmaceutical formulation
ZA96124B (en) A pharmaceutical formulation
GB9519363D0 (en) Pharmaceutical formulation
EG23826A (en) Pharmaceutical formulations
GB9523752D0 (en) Pharmaceutical formulations
EP0862431A4 (en) Pharmaceutical formulation
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
IL112521A0 (en) Pharmaceutical formulation
ZA958606B (en) A pharmaceutical formulation
GB9405856D0 (en) Pharmaceutical formulation
GB9416599D0 (en) Pharmaceutical formulation
GB9523566D0 (en) Pharmaceutical formulation
ZA96526B (en) Novel pharmaceutical formulation
AU3949093A (en) A pharmaceutical formulation
ZA964372B (en) A pharmaceutical formulation
ZA965367B (en) A pharmaceutical formulation
AP9801196A0 (en) Pharmaceutical preparation
SG47206A1 (en) Pharmaceutical compounds
ZA96122B (en) A pharmaceutical formulation
ZA96392B (en) Pharmaceutical formulations
ZA96123B (en) A pharmaceutical formulation
GB9500978D0 (en) Pharmaceutical formulations
GB9502786D0 (en) Pharmaceutical formulation
GB9525386D0 (en) Pharmaceutical formulation